[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.52.237. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 548
Citations 0
News From the Food and Drug Administration
November 17, 2015

Immunotherapy for Lung Cancer

JAMA. 2015;314(19):2015. doi:10.1001/jama.2015.15195

The FDA has approved one drug and expanded the use of another for patients with metastatic non–small cell lung cancer (NSCLC) that has progressed after treatment with other agents. Both drugs are checkpoint inhibitors that mobilize the immune system’s cancer-fighting ability (http://1.usa.gov/1JXCpmJ, http://1.usa.gov/1hgkNfa).

Pembrolizumab, marketed as Keytruda, and nivolumab, marketed as Opdivo, are monoclonal antibodies that block the programmed death-1 receptor on T cells from binding with the programmed death ligand-1 (PD-L1) on tumor cells. As a result, the immune system mounts a more robust response against cancerous tumors.

First Page Preview View Large
First page PDF preview
First page PDF preview
×